Philips Respironics Reaches Principle Agreement with US Department of Justice to Resolve Sleep and Respiratory Care Recall Investigations

Philips Respironics, the embattled subsidiary of the Dutch health technology giant Royal Philips, has reached a significant agreement in principle with the United States Department of Justice (DOJ) to settle long-standing criminal and civil investigations stemming from its massive global recall of sleep and respiratory care devices. This development marks a pivotal moment in one of the most complex corporate crises in the medical device industry, as the company seeks to move past the regulatory and financial turmoil that has defined its operations since 2021.

The agreement requires Philips to establish a provision of EUR 288 million, which was formally recorded in the company’s third-quarter financial results for 2026. While the settlement remains subject to the finalization of definitive legal documentation, the company anticipates that the payment will be executed during the first quarter of 2027. This resolution is intended to address the governmental scrutiny that followed the widespread discovery of potential health risks associated with the sound-abatement foam used in millions of the company’s CPAP, BiPAP, and mechanical ventilator units.

The Chronology of the Crisis

The origins of this legal and public health challenge date back to June 2021, when Philips Respironics initiated a voluntary recall of a vast array of its sleep and respiratory care products. The primary concern involved the polyester-based polyurethane (PE-PUR) foam used to reduce noise and vibration in these devices. Testing revealed that the foam could degrade over time, potentially releasing toxic particles and volatile organic compounds into the device’s air pathway, which patients then inhaled.

Following the initial recall, the situation escalated rapidly. In the months that followed, the US Food and Drug Administration (FDA) issued several high-level safety communications and inspection reports, criticizing the company’s internal safety testing protocols and its delay in notifying regulators about the known risks. By 2022, the US Department of Justice initiated an investigation into the matter, focusing on the company’s awareness of the risks and its communication strategies with both healthcare providers and the public.

The subsequent years saw a flurry of legal activity. In 2024, Philips entered into a comprehensive consent decree with the DOJ and the FDA, which mandated rigorous safety improvements and the appointment of independent monitors to oversee the company’s quality control systems. This latest agreement in principle represents the final major hurdle in the federal government’s investigation into the company’s conduct regarding the notification and management of the recall.

Investor Scrutiny and Corporate Governance

While the settlement with the DOJ provides a degree of clarity for Philips’ future, the company has faced significant internal pressure from its own shareholders. During the third quarter of 2026, the Enterprise Chamber of the Amsterdam Court of Appeal issued a ruling that denied requests from a group of activist investors seeking an independent, court-mandated investigation into Philips’ corporate governance and decision-making processes during the recall period.

The investors had argued that the company’s leadership failed to manage the recall effectively, leading to billions of euros in lost market capitalization. However, the court’s decision offers a measure of relief to Philips’ management team, reinforcing the board’s position that it has taken appropriate corrective actions. Despite this legal victory in the Netherlands, the incident has fundamentally altered the company’s investor relations strategy and its approach to transparency in medical device safety.

Financial Performance Amidst Legal Headwinds

Perhaps the most surprising aspect of the current financial report is the resilience of the Sleep and Respiratory Care division. Despite the severe reputational damage and the ongoing costs associated with the recall, the division reported an acceleration in sales growth to mid-single digits in the third quarter of 2026. This growth was largely attributed to a resurgence in demand for sleep therapy equipment in Japan and Europe, regions where the company has successfully rebuilt its supply chain and product safety reputation.

Within the broader "Connected Care" segment, which serves as the parent division for the sleep and respiratory business, the company reported a 5% increase in comparable sales. Furthermore, the adjusted EBITA (Earnings Before Interest, Taxes, and Amortization) margin for this segment improved by 190 basis points, reaching 13.3%. These figures suggest that Philips has managed to isolate the financial impact of the recall while simultaneously maintaining operational efficiency and market demand for its newer, updated medical technologies.

The Impact of the Consent Decree

The road to this settlement was paved by the formal consent decree finalized in previous years. This agreement forced Philips Respironics to halt the production of certain devices at key manufacturing sites until those facilities met stringent FDA safety standards. The decree did more than just mandate a pause in production; it required the company to overhaul its entire Quality Management System (QMS).

Under the oversight of a court-appointed monitor, Philips has been forced to integrate a more robust risk-assessment framework. For the medical device industry, this represents a significant shift toward higher accountability. Experts in the field of regulatory compliance suggest that the Philips case will serve as a textbook example of the risks associated with inadequate safety vigilance. The cost of the recall—which has already included a separate $1 billion settlement for patient injuries—far outweighs the cost of the original manufacturing modifications that might have prevented the issue entirely.

Broader Implications for the Medical Device Industry

The resolution of the DOJ investigation serves as a critical signal to the wider healthcare technology sector. The scale of the Philips recall is unprecedented in the modern era of respiratory medical devices, and the resulting legal and regulatory burden highlights the intensifying scrutiny applied by the FDA and the DOJ toward large-scale medical device manufacturers.

Manufacturers are now facing a new landscape defined by:

1. Heightened Transparency: Regulators are demanding earlier disclosure of device malfunctions, even if the clinical significance is not yet fully understood.
2. Stringent Supply Chain Audits: Companies are being pressured to verify the long-term biological safety of every component used in medical devices, including "invisible" materials like sound-dampening foam or adhesives.
3. Active Monitoring: The role of the "independent monitor" is becoming a standard feature of settlements, effectively ceding a degree of corporate autonomy to third-party oversight for years at a time.

Future Outlook and Leadership Response

Roy Jakobs, CEO of Royal Philips, has maintained a focus on the company’s "turnaround" strategy. In a recent statement, Jakobs framed the DOJ agreement as a necessary milestone for the company’s recovery. "We continue to make progress in resolving the consequences of the Sleep & Respiratory Care recall," Jakobs stated. "The Respironics agreement in principle with the US Department of Justice marks an important step in this process."

For Philips, the challenge ahead is to pivot away from the defensive posture it has maintained since 2021. With the DOJ settlement in place and the Amsterdam court rejecting further investigations, the company is finally in a position to reallocate management focus toward innovation rather than litigation. However, the legacy of the recall will persist for years, particularly as the company continues to fulfill its obligations under the consent decree and manages the long-term monitoring of patients who were affected by the faulty devices.

As Philips moves into 2027, the focus for the company will shift from crisis management to rebuilding its brand equity. The market has reacted with cautious optimism, noting that the company has effectively "cleared the decks" of its most significant legal liabilities. Whether this will lead to a full recovery of the company’s valuation remains a subject of debate among analysts, but the stability provided by the current agreement is undoubtedly the first step toward restoring long-term confidence in one of the world’s most recognizable medical technology brands.

The finalization of the documentation in the coming months will be closely watched by stakeholders and regulatory bodies alike. With the payment of the EUR 288 million provision, the financial chapter of this crisis will draw to a close, allowing Philips to focus on its core mission of providing advanced health technology solutions in an increasingly complex and regulated global market.